Flowrate-Independent indomethacin dry powder inhaler for potential treatment of pediatric asthma: In vitro aerodynamic and anti-inflammatory evaluation

IF 4.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Nazareth E. Ceschan , Andrea V. Dugour , Beatriz Behrend , Juan M. Figueroa , Hugh D.C. Smyth , Verónica Bucalá , María V. Ramírez Rigo
{"title":"Flowrate-Independent indomethacin dry powder inhaler for potential treatment of pediatric asthma: In vitro aerodynamic and anti-inflammatory evaluation","authors":"Nazareth E. Ceschan ,&nbsp;Andrea V. Dugour ,&nbsp;Beatriz Behrend ,&nbsp;Juan M. Figueroa ,&nbsp;Hugh D.C. Smyth ,&nbsp;Verónica Bucalá ,&nbsp;María V. Ramírez Rigo","doi":"10.1016/j.ejpb.2025.114870","DOIUrl":null,"url":null,"abstract":"<div><div>Asthma, a chronic respiratory condition affecting millions globally, is particularly common in children and a leading cause of emergency visits and hospitalizations. Characterized by airway inflammation and increased bronchial sensitivity, asthma is typically treated with inhaled corticosteroids. Despite their effectiveness, these treatments often face challenges related to adherence and adverse effects. Non-steroidal anti-inflammatory drugs (NSAIDs), though not traditionally used for asthma due to potential adverse reactions in sensitive patients, could be beneficial when administered via inhalation to minimize systemic side effects. In this work, an indomethacin (a NSAID) dry powder inhaler (DPI) is proposed for pediatric asthma treatment as a potential alternative for reducing doses of traditional anti-asthmatic therapies using corticosteroids. Crystalline microparticles, with mean volumetric diameter of 6.0 μm and suitable for inhalation, were obtained by jet-milling, an easy and cost-effective technology. Although the milled particles tended to agglomerate, they were readily dispersed through inhalers with different intrinsic resistances. Under pharmacopoeial conditions (4 KPa), mass median aerodynamic diameter values were 3.7–4.0 μm for inhalers with different intrinsic resistance while aerodynamic particle size distribution was narrow considering GSD was 1.5–1.7. The emitted fraction was high when assays were performed at a 4 KPa pressure drop, but decreased with lower pressure drops in subsequent tests. The fine particle fraction of indomethacin (indicating the emitted amount of drug entering the lungs) was independent of the inspiratory flowrate and inhaler internal resistance, making the formulation suitable for patients with different respiratory capabilities, like children. Finally, milled indomethacin demonstrated an anti-inflammatory effect similar to that of a topical corticosteroid in an asthmatic model.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"216 ","pages":"Article 114870"},"PeriodicalIF":4.3000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641125002474","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Asthma, a chronic respiratory condition affecting millions globally, is particularly common in children and a leading cause of emergency visits and hospitalizations. Characterized by airway inflammation and increased bronchial sensitivity, asthma is typically treated with inhaled corticosteroids. Despite their effectiveness, these treatments often face challenges related to adherence and adverse effects. Non-steroidal anti-inflammatory drugs (NSAIDs), though not traditionally used for asthma due to potential adverse reactions in sensitive patients, could be beneficial when administered via inhalation to minimize systemic side effects. In this work, an indomethacin (a NSAID) dry powder inhaler (DPI) is proposed for pediatric asthma treatment as a potential alternative for reducing doses of traditional anti-asthmatic therapies using corticosteroids. Crystalline microparticles, with mean volumetric diameter of 6.0 μm and suitable for inhalation, were obtained by jet-milling, an easy and cost-effective technology. Although the milled particles tended to agglomerate, they were readily dispersed through inhalers with different intrinsic resistances. Under pharmacopoeial conditions (4 KPa), mass median aerodynamic diameter values were 3.7–4.0 μm for inhalers with different intrinsic resistance while aerodynamic particle size distribution was narrow considering GSD was 1.5–1.7. The emitted fraction was high when assays were performed at a 4 KPa pressure drop, but decreased with lower pressure drops in subsequent tests. The fine particle fraction of indomethacin (indicating the emitted amount of drug entering the lungs) was independent of the inspiratory flowrate and inhaler internal resistance, making the formulation suitable for patients with different respiratory capabilities, like children. Finally, milled indomethacin demonstrated an anti-inflammatory effect similar to that of a topical corticosteroid in an asthmatic model.

Abstract Image

不依赖流量的吲哚美辛干粉吸入器用于儿童哮喘的潜在治疗:体外空气动力学和抗炎评价。
哮喘是一种影响全球数百万人的慢性呼吸系统疾病,在儿童中尤为常见,是急诊和住院的主要原因。哮喘的特点是气道炎症和支气管敏感性增加,通常用吸入皮质类固醇治疗。尽管这些治疗方法有效,但它们往往面临着与坚持和不良反应有关的挑战。非甾体抗炎药(NSAIDs),虽然传统上不用于哮喘,因为敏感患者有潜在的不良反应,但当通过吸入给药以减少全身副作用时,可能是有益的。在这项工作中,吲哚美辛(一种NSAID)干粉吸入器(DPI)被提议用于儿童哮喘治疗,作为减少使用皮质类固醇的传统抗哮喘治疗剂量的潜在替代方案。通过射流铣削工艺,获得了平均体积直径为6.0 μm、适合吸入的结晶微颗粒。虽然磨碎的颗粒倾向于凝聚,但它们很容易通过具有不同内在阻力的吸入器分散。在药典条件下(4 KPa),不同内阻吸入器的空气动力学粒径中值为3.7 ~ 4.0 μm,考虑GSD为1.5 ~ 1.7,空气动力学粒径分布较窄。当压力降为4 KPa时,发射分数很高,但在随后的测试中,压力降越低,发射分数就越低。吲哚美辛的细颗粒分数(表明药物进入肺部的释放量)不受吸入流量和吸入器内阻的影响,适合儿童等不同呼吸能力的患者。最后,磨粉吲哚美辛在哮喘模型中表现出与局部皮质类固醇相似的抗炎作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
8.80
自引率
4.10%
发文量
211
审稿时长
36 days
期刊介绍: The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics. Topics covered include for example: Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids) Aspects of manufacturing process design Biomedical aspects of drug product design Strategies and formulations for controlled drug transport across biological barriers Physicochemical aspects of drug product development Novel excipients for drug product design Drug delivery and controlled release systems for systemic and local applications Nanomaterials for therapeutic and diagnostic purposes Advanced therapy medicinal products Medical devices supporting a distinct pharmacological effect.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信